이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Zhejiang Xinguang Pharmaceutical 대차 대조표 상태

재무 상태 기준 확인 6/6

Zhejiang Xinguang Pharmaceutical 의 총 주주 지분은 CN¥866.5M 이고 총 부채는 CN¥0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 CN¥944.7M 및 CN¥78.2M 입니다. Zhejiang Xinguang Pharmaceutical 의 EBIT는 CN¥38.8M 이며 이자보상배율은 -1.6 입니다. CN¥735.8M 의 현금 및 단기 투자금을 보유하고 있습니다.

주요 정보

부채 비율

CN¥0

부채

이자 보상 비율	-1.6x
현금	CN¥735.84m
주식	CN¥866.54m
총 부채	CN¥78.17m
총 자산	CN¥944.72m

최근 재무 상태 업데이트

업데이트 없음

Recent updates

Zhejiang Xinguang Pharmaceutical (SZSE:300519) Has Announced That Its Dividend Will Be Reduced To CN¥0.40

May 26

Calculating The Intrinsic Value Of Zhejiang Xinguang Pharmaceutical Co., Ltd. (SZSE:300519)

Apr 16

Zhejiang Xinguang Pharmaceutical Co., Ltd.'s (SZSE:300519) Low P/E No Reason For Excitement

Feb 26

재무 상태 분석

단기부채: 300519 의 단기 자산 ( CN¥799.9M )이 단기 부채( CN¥69.3M ).

장기 부채: 300519 의 단기 자산( CN¥799.9M )이 장기 부채( CN¥8.9M ).

부채 대 자본 내역 및 분석

부채 수준: 300519 부채가 없습니다.

부채 감소: 300519 5년 전에 부채가 없었습니다.

부채 범위: 300519 은 부채가 없으므로 영업현금흐름으로 충당할 필요가 없습니다.

이자 보장: 300519 에는 부채가 없으므로 이자 지불에 대한 보장은 문제가 되지 않습니다.

Zhejiang Xinguang Pharmaceutical 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

Recent updates

Zhejiang Xinguang Pharmaceutical (SZSE:300519) Has Announced That Its Dividend Will Be Reduced To CN¥0.40

Dividend reduced to CN¥0.40

New major risk - Revenue and earnings growth

Full year 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.68 in FY 2022)

Now 27% overvalued

Calculating The Intrinsic Value Of Zhejiang Xinguang Pharmaceutical Co., Ltd. (SZSE:300519)

Investor sentiment deteriorates as stock falls 15%

Zhejiang Xinguang Pharmaceutical Co., Ltd.'s (SZSE:300519) Low P/E No Reason For Excitement

Investor sentiment improves as stock rises 16%

Now 22% overvalued

Investor sentiment deteriorates as stock falls 20%

Third quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.18 in 3Q 2022)

New major risk - Dividend sustainability

Zhejiang Xinguang Pharmaceutical Co., Ltd. Approves the Cash Dividend for 2022, Payment on 30 May 2023

Zhejiang Xinguang Pharmaceutical Co., Ltd. Approves the Cash Dividend

First quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.19 in 1Q 2022)

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.19 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.12 in 2Q 2021)

Zhejiang Xinguang Pharmaceutical Co., Ltd. Approves Profit Distribution for 2021

Less than half of directors are independent

Zhejiang Xinguang Pharmaceutical Co., Ltd. Proposes Final Dividend for 2021

Full year 2021 earnings released: EPS: CN¥0.71 (vs CN¥0.62 in FY 2020)

Investor sentiment deteriorated over the past week

Now 23% undervalued after recent price drop

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Now 21% undervalued

Investor sentiment improved over the past week

Now 21% undervalued

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.18 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.12 in 2Q 2020)

Investor sentiment improved over the past week

Zhejiang Xinguang Pharmaceutical Co., Ltd. Approves Final Cash Dividend on A Shares for the Year 2020, Payable on May 28, 2021

Investor sentiment improved over the past week

Zhejiang Xinguang Pharmaceutical Co., Ltd. Proposes the Final Cash Dividend for 2020

Full year 2020 earnings released: EPS CN¥0.62 (vs CN¥0.59 in FY 2019)

New 90-day low: CN¥13.57

New 90-day low: CN¥16.09

Investor sentiment deteriorated over the past week

New 90-day low: CN¥17.00

Third quarter earnings released

Market bids up stock over the past week

New 90-day high: CN¥23.30

New 90-day high - CN¥20.29

Earnings released

Zhejiang Xinguang Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 26, 2020

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

건강한 기업 발견하기